Holger Sültmann, Ph.D.

Professor of Applied Genome Research

Head of Cancer Genome Research Group,
German Cancer Research Center and National Center for Tumor Diseases

 

National Center for Tumor Diseases (NCT)
Im Neuenheimer Feld 460
69120 Heidelberg

Phone:+49 6221 56-5934
Opens window for sending emailE-Mail
Opens external link in new windowHomepage

 

 

Research Interests:

 

 


Opens internal link in current windowShort CV

Opens internal link in current windowMemberships/Committee Assignments
Opens internal link in current windowProjects

Opens internal link in current windowPatents
Opens internal link in current windowTeam
Opens internal link in current windowSelected Publications


 

 

Curriculum Vitae

1991Diploma in Biochemistry, University of Tübingen, Germany
1994Dr. rer. nat. (PhD), University of Tübingen
1994-2000Postdoc and Group Head, Div. of Immunogenetics, Max-Planck-Institute for Biology, Tübingen
2000-2010Group head, Div. of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg
2001Habilitation in Genetics, University of Tübingen
since 2010Head of Research Group Cancer Genome Research
2012Full professor for Applied Genome Research, Medical Faculty, Heidelberg University

 

 

Memberships/Committee Assignments

2006-2011Coordinator of interdisciplinary genome research projects on prostate cancer (BMBF, Austrian National Foundation)
2010-2013Co-coordinator of the German ICGC project on prostate cancer genome sequencing (BMBF)
since 2007Member of The German Cancer Society
since 2011Member of the Precision Oncology Program Committee and Molecular Tumor Board at NCT Heidelberg
since 2012Principal Investigator of the Translational Research Center Heidelberg (TLRC) and the German Center for Lung Research (DZL)

Projects

  1. Transcriptome analysis of cancer (non small cell lung cancer, prostate cancer)
  2. Functional characterization of diagnostic miRNA markers
  3. Genomic and epigenomic determinants of therapy resistance in malignant tumors (non small cell lung cancer, colorectal cancer)
  4. Liquid biopsy for tumor diagnosis and prognosis


Patents

Publication No.Publication DateInventor/ApplicantTitle
EP13152066.0, 21.1.20132013Kaduthanam S, Kuner R, Meister M, Muley T, Sültmann H. Serum miRNA-142-3p as prognostic marker in operable (low-grade) pulmonary adenocarcinoma.
EP 09 174 455.7, 2009; PCT/EP2010/066515; US-2012-0264638, 20122009, 2012Brase J, Kuner R, Johannes M, Beißbarth T, Fälth M, Schlomm T, Haese A, Steuber T, Sültmann H. Circulating miRNAs as non-invasive markers for the prediction of tumor progression in prostate cancer.
EP 11162979.6, 20112011Schweiger MR, Lehrach H, Börno S, Sültmann H, Sauter G, Schlomm T. Epigenetische Marker zur Prostata-Tumor-Diagnostik. Gemeinschaftserfindung der Max-Planck-Gesellschaft.

Team

Senior Scientists and Postdocs

PD Dr. Sabine Klauck

Dr. Ruprecht Kuner

Dr. Vladimir Kuryshev

Dr. Doreen Heckmann

Dr. Uwe Schirmer

 

PhD students

Sajo Kaduthanam

Julia Pickl

Leonie Ratz

 

Master student

Steffen Dietz

 

Technical assistants

Sabrina Gerhardt

Denise Keitel

Simon Ogrodnik

Selected Publications

  1. Sültmann H, Sato A, Murray BW, Takezaki N, Geisler R, Rauch GJ, Klein J. Conservation of Mhc Class III Region Synteny Between Zebrafish and Human as Determined by Radiation Hybrid Mapping. J. Immunol. 165, 6984-6993, 2000
     
  2. Sültmann H, v. Heydebreck A, Huber W, Kuner R, Buneß A, Vogt M, Gunawan B, Vingron M, Füzesi L, Poustka A. Gene expression in kidney cancer is associated with cytogenetic abnormalities, metastasis formation, and patient survival. Clin. Canc. Res. 11(2), 646-655, 2005

  3. Kuner R, Muley T, Meister M, Schnabel P, Ruschhaupt M, Buneß A, Poustka A, Sültmann H*, Hoffmann H*. Gene expression analysis of macrodissected non-small cell lung cancer samples suggests considerable molecular differences between histological subtypes. Lung Cancer 63:32-8, 2009

  4. Brase JC, Johannes M, Schlomm T, Fälth M, Haese A, Steuber T, Beißbarth T, Kuner R, Sültmann H. Circulating micro RNAs are correlated with tumor progression in prostate cancer. Int. J. Cancer 128(3):608-16, 2011

  5. Weischenfeldt J*, Simon, R*, Feuerbach L*, Schlangen K*, Weichenhan D*, Minner S*, Wuttig D*, Warnatz H-J, Stehr H, Rausch T, Jäger N, Gu L, Bogatyrova O, Claus R, Eils J, Eils R, Gerhäuser C, Huang P-H, Hutter B, Kabbe R, Lawerenz C, Radomski S, Bartholomä C, Fälth M, Gade S, Schmidt M, von Kalle C, Benes V, Stütz AM, Zichner T, Mader M, Amstislavskiy V, Avci M, Lehrach H, Parkhomchuk A, Sultan M, Burkhardt L, Gräfen M, Huland H, Kluth M, Krohn A, Sirma H, Stumm L, Sültmann H*, Sauter G*, Plass C*, Brors B*, Yaspo ML*, Korbel JO*, Schlomm T.*. Integrative genomic analyses reveal androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell, 23(2):159-70, 2013

  6. Kaduthanam S, Gade S, Meister M, Brase JC, Johannes M, Dienemann H, Warth A, Schnabel PA, Herth FJ, Sültmann H, Muley T, Kuner R. Serum miR-142-3p is associated with early relapse in operable lung adenocarcinoma patients. Lung Cancer 80(2); 223-227, 2013

  7. Ridder K, Keller S, Dams M, Rupp AK, Schlaudraff J, Del Turco D, Starmann J, Macas J, Depboylu C, Landfried B, Deller T, Plate KH, Höglinger G, Sültmann H, Altevogt P, Momma S. Extracellular vesicle-mediated transfer of genetic information between the hematopoietic system and the brain in response to inflammation. PLOS Biology 12(6), e1001874, 2014

  8. Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Fälth M, Stindt J, Kubitz R, Sültmann H, Urban S. Hepatitis B virus exploits sodium taurocholate co-transporting polypeptide (NTCP) for entering hepatocytes in a species-specific manner. Gastroenterology 146, 1070-1083, 2014